Clinical trials: sponsored by Peking University First Hospital
Psoriatic Arthritis, Upadacitinib
Upadacitinib Versus IL-17 Inhibitors in Patients With Psoriatic Arthritis
Psoriatic arthritis (PsA) is a chronic inflammatory disease with heterogeneous musculoskeletal and dermatologic manifestations, leading to significant functional impairment and reduced quality of life.
- Conditions
- Psoriatic Arthritis, Upadacitinib, Interleukin-17 Inhibitors
- Trial name
- UVIPWP (NCT07386717)
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Peking University First Hospital
Pancreatic Cancer Non-resectable
Nimotuzumab Combined With Chemoradiotherapy in the Treatment of Unresectable Locally Advanced or Oligometastatic Pancreatic Cancer
This study is a prospective, single-arm trial, aiming to enroll 30 patients with unresectable locally advanced or oligometastatic pancreatic cancer.
- Trial name
- NCT07386704
- Testing
- Nimotuzumab combined with chemoradiotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University First Hospital
Prostate Cancer
The Development and Validation of MRI-AI-based Predictive Models for csPCa
This study retrospectively included patients who underwent prostate magnetic resonance imaging (MRI) and subsequent ultrasound-guided prostate biopsy at Peking University First Hospital from January 2019 to December 2023, and…
- Trial name
- NCT06842264
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- Peking University First Hospital
Radiation Therapy, Metastatic Renal Cancer
SABR Combined With Targeted Therapy and Anti-PD-1 for Recurrent or Metastatic Renal Cancer
Renal cancer ranks seventh in incidence among men and sixth among women in the Beijing area, with Peking University First Hospital treating over 1,000 kidney cancer patients annually.
- Conditions
- Radiation Therapy, Metastatic Renal Cancer, Recurrent Renal Cell Cancer
- Trial name
- COSTAR (NCT06583070)
- Testing
- Radiation therapy, Targeted and immunotherapy
- Where
- 2 sites in China
- Volunteers
- 300 people
- Sponsor
- Peking University First Hospital
Breast Neoplasms、Lung Neoplasms、Pancreatic Neoplasms
68Ga-PFA2 PET Imaging for the Diagnosis of Annexin A2-Positive Tumors
Tumor metastasis and invasion are the leading causes of cancer-related deaths, with over 90% of cancer patients dying from distant metastasis.
- Trial name
- NCT07331532
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Peking University First Hospital
Elderly, Surgery
Dexmedetomidine Supplemented Analgesia and Incidence of Postoperative Delirium
Delirium is a frequently occurred cerebral complication in elderly patients after surgery, and its occurrence is associated with worse outcomes.
- Conditions
- Elderly, Surgery, Analgesia, Dexmedetomidine
- Trial name
- NCT03012984
- Testing
- Dexmedetomidine supplemented morphine analgesia, Morphine analgesia
- Where
- 12 sites in China
- Volunteers
- 1,500 people
- Sponsor
- Peking University First Hospital
Prostate Cancer, Community-based Screening
Establishment and Promotion of an AI-Based Early Warning System for Prostate and Bladder Cancer Screening in the Male Community Population of Beijing
Prostate cancer is one of the most common malignancies in the male genitourinary system, and it is also the cancer with the fastest-growing incidence and mortality rates among men in China.
- Trial name
- NCT07319923
- Testing
- No intervention
- Where
- China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
Urothelial Carcinoma
Adjuvant Radioimmunotherapy Compared With Adjuvant Chemotherapy for UTUC
This study is an ambispective cohort observational study to analyze the efficacy of adjuvant radioimmunotherapy (radiotherapy and immunotherapy) compared with adjuvant chemotherapy in patients with the upper urinary tract…
- Trial name
- NCT06120374
- Testing
- Radiotherapy, Chemotherapy, Immunotherapy
- Where
- 3 sites in China
- Volunteers
- 178 people
- Sponsor
- Peking University First Hospital
Acute Urinary Retention, LUTS(Lower Urinary Tract Symptoms)
Perioperative Tamsulosin for Treating Voiding Dysfunction Following Prostate Biopsy
The goal of this clinical trial is to learn if the drug Tamsulosin Hydrochloride works to treat urination difficulties after a prostate biopsy in men.The main questions it aims to answer are: Does Tamsulosin Hydrochloride lower…
- Trial name
- NCT07276919
- Testing
- Tamsulosin 0.2mg
- Where
- China
- Volunteers
- 1,844 people
- Sponsor
- Peking University First Hospital
Prostate Cancer
Darolutamide+ADT Post-RP w/o ePLND in hrPC: Briganti 2019
The goal of this clinical trial is to evaluate whether adjuvant darolutamide plus androgen-deprivation therapy (ADT) can reduce post-operative recurrence and improve disease control in high-risk prostate cancer patients-defined…
- Trial name
- NCT07282197
- Testing
- Darolutamide (BAY 1841788)
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University First Hospital
Upper Urinary Tract Urothelial Carcinoma
A Clinical Study of the Efficacy and Safety of Disitamab Vedotin in Combination With Radiotherapy for the Adjuvant Treatment of HER2 Overexpressing UTUC Patients With High Risk Factors for Recurrence After Radical Surgery
In this study, 60 patients with HER2 overexpression UTUC with high-risk recurrence factors after radical surgery were proposed to be enrolled, and were assigned to Cohort I (receiving adjuvant therapy group) and Cohort II…
- Trial name
- NCT06210490
- Testing
- Disitamab Vedotin, Radiotherapy, Standard of Care
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University First Hospital
Cushing's Syndrome, Postoperative
Contralateral Adrenal Volume Predicts Duration of Postoperative Steroid Replacement Therapy in Non-ACTH-dependent Hypercortisolism
To identify preoperative factors influencing the duration of steroid replacement therapy after adrenalectomy/adrenal-sparing surgery in patients with non-ACTH-dependent hypercortisolism.
- Conditions
- Cushing's Syndrome, Postoperative, Glucocorticoid, Prediction
- Trial name
- NCT07282223
- Testing
- observational diagnostic model development
- Where
- China
- Volunteers
- 121 people
- Sponsor
- Peking University First Hospital
Primary Aldosteronism
Multi-omics Studies of Primary Aldosteronism
Primary aldosteronism is a prevalent yet underdiagnosed cause of secondary hypertension, contributing to significant cardiovascular morbidity and renal dysfunction.
- Trial name
- NCT07111351
- Testing
- Without intervention
- Where
- China
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
Intensive Care Unit, Mechanical Ventilation
Night-time Dexmedetomidine-esketamine Infusion and Sleep Quality in ICU Patients
Dexmedetomidine and ketamine are both suggested for sedation and analgesia in ICU patients. Recent studies suggest that low-dose dexmedetomidine or ketamine/esketamine may improve sleep quality of ICU patients.
- Conditions
- Intensive Care Unit, Mechanical Ventilation, Dexmedetomidine, Esketamine
- Trial name
- NCT05718024
- Testing
- Dexmedetomidine-esketamine, Routine sedation and analgesia
- Where
- China
- Volunteers
- 174 people
- Sponsor
- Peking University First Hospital
Autoimmune Diseases
Complement C5 mAb in the Treatment of Anti-GBM Disease
Anti-GBM disease is the most severe form of glomerulonephritis. Despite of the standard treatment including plasmapheresis and immunosuppressant, 70% of the patients still go into end-stage kidney disease.
- Trial name
- NCT06513338
- Testing
- Eculizumab
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Peking University First Hospital
Adrenal Incidentalomas, Thoracic CT-scan
Artificial Intelligence Used in Screening Adrenal Nodules
By collecting chest low-dose spiral CT plain scan images, extracting effective features from the adrenal gland regions, training and validating an artificial intelligence-based automatic diagnostic algorithm for adrenal nodules…
- Trial name
- NCT07198152
- Testing
- None intervention
- Where
- China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
Salivary Gland Neoplasm Duct
Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma
The purpose of the study is to evaluate the efficacy and safety of rezvilutamide in combination with androgen deprivation therapy (ADT) in participants with androgen receptor (AR) positive, high-risk salivary duct carcinoma…
- Trial name
- NCT06348264
- Testing
- Rezvilutamide, Leuprolide Acetate
- Where
- 2 sites in China
- Volunteers
- 37 people
- Sponsor
- Peking University First Hospital
Primary Aldosteronism, Adrenal Tumor
Comparative Study of Perioperative Cardiac Injury in Patients With Functional Adrenal Tumors
The main goal of this study is to follow patients with functional adrenal tumors during the time before and after their surgery.
- Conditions
- Primary Aldosteronism, Adrenal Tumor, Cushing s Syndrome, Pheochromocytoma/Paraganglioma (PPGL)
- Trial name
- NCT07182175
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Peking University First Hospital
Inflamatory Bowel Disease
Construction and Validation of a Predictive Model for the Efficacy of Different Biologics in Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) is a group of chronic progressive gastrointestinal diseases that can recur throughout life and for which there is no cure.
- Trial name
- NCT07181525
- Testing
- anti-cytokine antibodies, anti-integrin antibodies
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Peking University First Hospital
Chronic Kidney Disease (Stages 3b-5)
Monitoring Hyperkalemia Using Point-of-care AI-enabled ECG Device Among Patients With Chronic Kidney Disease Stages 3b-5
The clinical trial will be conducted in a real-world outpatients setting with the goal of learning if monitoring serum potassium frequently among patients with moderate-to-advanced stages of chronic kidney disease leading to…
- Trial name
- POCKET (NCT06901960)
- Testing
- A mobile artificial intelligence-enhanced electrocardiogram device estimating plasma potassium categories (<5 mmol/L, 5 - <5.5 mmol/L, 5.5 - <6.0 mmol/L and ≥ 6.0 mmol/L)
- Where
- 3 sites in China
- Volunteers
- 1,066 people
- Sponsor
- Peking University First Hospital